Infection News

Since 2016, five children in the United States have been diagnosed with extensively drug-resistant typhoid fever after traveling to or from Pakistan, where a large ongoing typhoid outbreak has sickened more than 5,300 people, according to a report published today in MMWR.

Nearly 4% of patients with HIV who received hepatitis A vaccinations during an outbreak demonstrated seroreversion, most of whom had HIV viremia and lower CD4 lymphocyte counts compared with those who achieved seroconversion, according to recently published data.

Researchers observed significant fibrosis in more than one-third of patients with hepatitis B and HIV coinfection undergoing long-term combination antiretroviral therapy with viral suppression, according to a study published in American Journal of Gastroenterology.

Researchers discovered diverse hepatitis C genotype 4 strains and new genotype 7 strains in sub-Saharan African countries with NS3 and NS5A polymorphisms associated with resistance to direct-acting antivirals in other genotypes, according to recently published data.

Mavyret was safe and efficacious for patients with chronic hepatitis C who underwent liver or kidney transplantation, according to a recently published study.

The safety and efficacy of direct-acting antivirals for hepatitis C have begun to move HCV from the forefront of chronic liver disease into the realm of potential elimination. Many researchers are now focusing on the next task: improved care and possible cure of other viral hepatitis infections.

Results from a national survey showed that hepatitis C prevalence was higher in the West and Appalachian states between 2013 and 2016 compared with other areas, as reported in JAMA Network Open.

Eiger BioPharmaceuticals received FDA breakthrough therapy designation for lonafarnib, a prenylation inhibitor designed to treat hepatitis D, according to a press release.

Extrahepatic cancer was more common in patients with hepatitis C and was the leading cause of death in patients who achieved sustained virologic response compared with the general population, according to results of a French cohort study.

The FDA announced revisions to the Viread label to include use in pediatric patients aged 2 years to less than 12 years with chronic hepatitis B based on 48-week safety and efficacy data.